Journal Article10.1056/NEJMRA030831
Mechanisms of bone metastasis.
2.8K
TL;DR: Bone metastasis causes severe bone pain and can result in fractures without any injury, as well as other life-threatening conditions, and patients with prostate cancer who usually have bone metastasis that shows increased new bone formation also have increased bone destruction in the same lesions.
read more
Abstract: Extract: Cancer frequently spreads to bone, a process termed bone metastasis. Up to 70% of patients with breast cancer or prostate cancer, and 15 to 30% of patients with lung, colon, bladder or kidney cancer develop bone metastasis. Once tumors go to bone, such as in patients with breast cancer or prostate cancer, they are incurable, and only 20% of patients with breast cancer are still alive five years after they are found to have bone metastasis. It is estimated that about 350,000 people die with bone metastasis each year in the United States. Bone metastasis causes severe bone pain and can result in fractures without any injury, as well as other life-threatening conditions. There are two major types of bone metastasis, one in which bone destruction is the predominant feature and the other one in which new bone formation is predominant. Bone metastasis where bone destruction is the predominant feature is known as osteolytic, and that in which new bone formation is the primary feature is called osteoblastic. This classification for metastasis is really two extremes of a continuum because many patients can have both osteolytic and osteoblastic or mixtures of both in their bone metastasis. In fact, patients with prostate cancer who usually have bone metastasis that shows increased new bone formation also have increased bone destruction in the same lesions.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Dissemination and growth of cancer cells in metastatic sites
TL;DR: Inhibition of the growth of metastases in secondary sites offers a promising approach for cancer therapy and could help to improve the treatment of metastatic disease.
4.2K
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker,Sten Nilsson,Sten Nilsson,D. Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,Paweł Wiechno,John P Logue,Mihalj Seke,Anders Widmark,D. C. Johannessen,Peter Hoskin,David Bottomley,Nicholas D. James,Arne Solberg,Isabel Syndikus,Ján Kliment,S. Wedel,S. Boehmer,Marcos F. Dall'Oglio,Lars Franzén,Robert E. Coleman,Nicholas J. Vogelzang,C.G. O'Bryan-Tear,K. Staudacher,J. Garcia-Vargas,M. Shan,Øyvind S. Bruland,Oliver Sartor +30 more
TL;DR: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival and was associated with low myelosuppression rates and fewer adverse events.
Tumor metastasis: mechanistic insights and clinical challenges
TL;DR: In this article, complex and redundant pathways involving the tumor cell and the microenvironment mediate tumor invasion at the primary site, survival and arrest in the bloodstream, and progressive outgrowth at a distant site.
2.1K
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison Stopeck,Allan Lipton,Jean-Jacques Body,Guenther G. Steger,Katia Tonkin,Richard De Boer,Mikhail Lichinitser,Yasuhiro Fujiwara,Denise A. Yardley,María Viniegra,Michelle Fan,Qi Jiang,Roger Dansey,Susie Jun,Ada Braun +14 more
TL;DR: With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
1.5K
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay,Elizabeth P. Ryan,Graham Pawelec,Wamidh H. Talib,John Stagg,Eyad Elkord,Terry Lichtor,William K. Decker,Richard L. Whelan,H. M. C. Shantha Kumara,Emanuela Signori,Kanya Honoki,Alexandros G. Georgakilas,Amr Amin,William G. Helferich,Chandra S. Boosani,Gunjan Guha,Maria Rosa Ciriolo,Sophie Chen,Sulma I. Mohammed,Asfar S. Azmi,W. Nicol Keith,Alan Bilsland,Dipita Bhakta,Dorota Halicka,Hiromasa Fujii,Katia Aquilano,S. Salman Ashraf,Somaira Nowsheen,Xujuan Yang,Beom K. Choi,Byoung S. Kwon +31 more
TL;DR: The advances made toward understanding the basis of cancer immune evasion are discussed, the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection are summarized and some natural agents and phytochemicals merit further study.
1.4K
References
RANK is essential for osteoclast and lymph node development.
William C. Dougall,Moira Glaccum,Keith Charrier,Kathy Rohrbach,Kenneth Brasel,T De Smedt,E Daro,Jeffrey S. Smith,Mark E. Tometsko,C. R. Maliszewski,Allison P. Armstrong,V Shen,S Bain,David Cosman,Dirk M. Anderson,Philip J. Morrissey,Jacques J. Peschon,JoAnn C. L. Schuh +17 more
TL;DR: Investigating the physiological role of the TNF receptor (TNFR) family member, RANK, revealed that RANK provides critical signals necessary for lymph node organogenesis and osteoclast differentiation.
1.5K
Evidence for a Novel Gene Associated With Low Tumor Metastatic Potential
Patricia S. Steeg,Generoso Bevilacqua,Laszlo Kopper,Unnur P. Thorgeirsson,James E. Talmadge,Lance A. Liotta,Mark E. Sobel +6 more
TL;DR: The predicted carboxy-terminal protein sequence encoded by the pNM23 cDNA clone is novel compared with Genebank animal, bacterial, and viral sequences and may be associated with intrinsic aggressiveness.
1.3K
A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
Paul Basset,Jean-Pierre Bellocq,Catherine Wolf,I. Stoll,P. Hutin,J. M. Limacher,Osvaldo L. Podhajcer,Chenard Mp,M. C. Rio,Pierre Chambon +9 more
TL;DR: The suggestion is that stromelysin-3 is one of the stroma-derived factors that have long been postulated to play an important part in progression of epithelial malignancies.
1.2K
The clinical course of bone metastases from breast cancer.
TL;DR: The duration of survival in patients with carcinoma of the breast seen in this Unit was similar to responding patients, suggesting a tumour response may occur in the absence of discernable radiological evidence of healing.
1.1K
TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
Juan Juan Yin,Katri Selander,John M. Chirgwin,Mark Dallas,Barry Grubbs,Rotraud Wieser,Joan Massagué,Gregory R. Mundy,Theresa A. Guise +8 more
TL;DR: An important role is demonstrated in the development of breast cancer metastasis to bone, via the TGF-beta receptor-mediated signaling pathway in tumor cells, and it is suggested that the bone destruction is mediated by PTHrP.